Clinical-stage biotech firm Capricor Therapeutics, Inc. (NASDAQ: CAPR) is dedicated to developing revolutionary therapeutic options for Duchenne muscular dystrophy (DMD) and other medical conditions that are currently untreatable. The company's flagship drug candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that has completed phase III clinical trials for late-stage DMD treatment. Capricor is also focused on the development of StealthX, an engineered exosome platform technology that has generated two vaccine candidates, STX-S and STX-N, which generated an immune response against two SARS-CoV-2 proteins, spike and nucleocapsid. The company also has ongoing projects to develop therapeutics and vaccines for infectious and monogenic diseases and potential indications. Additionally, Capricor is currently developing CAP-2003, a treatment option that is in pre-clinical development for trauma-related injuries and conditions. The San Diego, California-based company collaborates with Lonza Houston, Inc. for the clinical manufacture of CAP-1002 and other cell therapy candidates aimed at treating DMD and other indications. Capricor Therapeutics was founded in 2005.
Capricor Therapeutics's ticker is CAPR
The company's shares trade on the NASDAQ stock exchange
They are based in Los Angeles, California
There are 11-50 employees working at Capricor Therapeutics
It is capricor.com
Capricor Therapeutics is in the Healthcare sector
Capricor Therapeutics is in the Biotechnology industry
The following five companies are Capricor Therapeutics's industry peers: